Study of ADX-324 for preventing HAE attacks
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have type I or type II hereditary angioedema (HAE).
- You have had at least 1 HAE attack in the past month or 2 attacks in the past 2 months.
- You can use an acute medication to treat HAE attacks (like a shot for attacks).
- You cannot be currently using long-term HAE prevention drugs like CINRYZE, HAEGARDA, RUCONEST, ORLADEYO, TAKHZYRO, or androgens (like danazol).
- You cannot have other forms of angioedema or serious liver/kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This trial tests if sebetralstat can prevent swelling attacks before medical procedures in people with HAE types I or II. You take the medicine short-term before your procedure to see if it helps protect you from an attack.
This trial tests an oral medication (sebetralstat) for treating angioedema attacks in children aged 2 to 11 with hereditary angioedema (HAE). The goal is to see if this medicine can safely relieve swelling and pain during an attack, offering a convenient at-home treatment option for kids.
This expanded access program offers an investigational medication called deucrictibant immediate-release to people with hereditary angioedema (HAE) who have no good treatment options for their acute attacks. It aims to provide relief when other approved therapies haven't worked or aren't suitable.
This study lets people who were already taking berotralstat through earlier BioCryst studies keep the treatment going. It looks at safety and ongoing benefit for preventing hereditary angioedema attacks.
Hear when a new Hereditary Angioedema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.